Karn Wijarnpreecha is a Gastroenterology physician affiliated with University of Arizona. OpenAlex indexes 397 publications with 7,650 citations (h-index 47).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1441 N 12th St Fl 2
Phoenix, AZ 850062837
Telephone
602-521-5800Provider last certified this registry record 25 Sept 2025.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Madrigal PharmaceuticalsProgram year20253 payments
- ABBVIE INC.Program year20241 payment
- Salix Pharmaceuticals, a division of Bausch Health US, LLCProgram year20232 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
55%Beta blocker24.3%Carvedilol100%Part D≥38 patientsAldosterone antagonist (MRA)20.4%Spironolactone100%Part D≥24 patients+ 1 more class in this area
Metabolism & gastrointestinal
45%Rifamycin Antibacterial19.7%Xifaxan100%Part D≥16 patientsOsmotic Laxative15.5%Lactulose73%Gavilyte-G27%Part D≥21 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- What Is New in Metabolic Dysfunction-Associated Steatotic Liver Disease in Lean Individuals: From Bench to Bedside
Journal of Clinical Medicine
2024 - Disparities in steatosis prevalence in the United States by Race or Ethnicity according to the 2023 criteria
Communications Medicine
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Joseph Alpert, MD
University of Arizona
Karl Kern, MD
University of Arizona
Peter Reaven, MD
University of Arizona
Alison Stopeck, MD
University of Arizona
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”